Mechanism of Action of Amivantamab
Introduction Amivantamab is a targeted anticancer monoclonal antibody used in selected patients with non-small cell lung cancer, commonly abbreviated as NSCLC. It is marketed under the brand name Rybrevant as intravenous amivantamab-vmjw. A subcutaneous formulation, Rybrevant Faspro, contains amivantamab with hyaluronidase-lpuj, but the key anticancer antibody component is amivantamab. Pharmacologically, amivantamab is a bispecific antibody … Read more